Literature DB >> 20800392

Predicting neurosensory disabilities at two years of age in a national cohort of extremely premature infants.

Katrine Tyborg Leversen1, Kristian Sommerfelt, Arild Rønnestad, Per Ivar Kaaresen, Theresa Farstad, Janne Skranes, Ragnhild Støen, Irene Bircow Elgen, Siren Rettedal, Geir Egil Eide, Lorentz M Irgens, Trond Markestad.   

Abstract

BACKGROUND: Extreme prematurity carries a high risk of neurosensory disability. AIMS: Examine which information obtained pre-, peri- and postnatally may be predictive of neurosensory disabilities at 2 years of age. STUDY
DESIGN: Prospective observational study of all infants born in Norway in 1999 and 2000 with gestational age (GA) 22-27 completed weeks or birth weight (BW) of 500-999 g. OUTCOME MEASURES: Incidence of neurosensory disabilities.
RESULTS: Of 373 surviving children, 30 (8%) had major neurosensory disabilities (26 CP, 6 blind, 3 deaf), and a further 46 (12%) had minor visual or hearing disabilities. The rate of major neurosensory disabilities was 19 of 99 (19%) for children with GA 23-25 vs. 8 of 189 (4%) for GA 26-27 weeks (p<0.001). In a multivariable model, only morbidities detected in the neonatal intensive care unit (NICU) were associated with major neurosensory disabilities; adjusted odds ratios (95% confidence intervals) were 68.6 (18.7, 252.2) for major abnormalities on cerebral ultrasound, 6.8 (1.7, 27.4) for retinopathy of prematurity (ROP) grade>2, 3.2 (1.0, 9.7) for ROP grade 1-2, 6.5 (1.9, 22.3) for prolonged use (> or = 21 days) of steroid treatment for lung disease and 3.1 (1.0, 9.4) for clinical chorioamnionitis. The visual outcome was strongly related to the degree of ROP (p<0.001), and all who had a normal hearing screen in the NICU had normal hearing at 2 years.
CONCLUSION: NICU morbidities, rather than GA or intrauterine growth are the significant predictors of major neurosensory disabilities among extreme prematurity surviving to discharge from the NICU.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20800392     DOI: 10.1016/j.earlhumdev.2010.07.009

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  6 in total

1.  Antecedents and correlates of visual field deficits in children born extremely preterm.

Authors:  Mari Holm; Michael E Msall; Jon Skranes; Olaf Dammann; Elizabeth Allred; Alan Leviton
Journal:  Eur J Paediatr Neurol       Date:  2014-10-12       Impact factor: 3.140

2.  Birth weight independently affects morbidity and mortality of extremely preterm neonates.

Authors:  Apostolos Mamopoulos; Stamatios Petousis; John Tsimpanakos; Sophia Masouridou; Kelly Kountourelli; Chrysoula Margioula-Siarkou; Maria Papouli; David Rousso
Journal:  J Clin Med Res       Date:  2015-05-08

3.  Systematic Review of Cerebral Palsy Registries/Surveillance Groups: Relationships between Registry Characteristics and Knowledge Dissemination.

Authors:  Donna S Hurley; Theresa Sukal-Moulton; Deborah Gaebler-Spira; Kristin J Krosschell; Larissa Pavone; Akmer Mutlu; Julius Pa Dewald; Michael E Msall
Journal:  Int J Phys Med Rehabil       Date:  2015-03-23

4.  Respiratory morbidity through the first decade of life in a national cohort of children born extremely preterm.

Authors:  Kaia Skromme; Maria Vollsæter; Knut Øymar; Trond Markestad; Thomas Halvorsen
Journal:  BMC Pediatr       Date:  2018-03-07       Impact factor: 2.125

5.  Mortality, neonatal morbidity and two year follow-up of extremely preterm infants born in The Netherlands in 2007.

Authors:  Cornelia G de Waal; Nynke Weisglas-Kuperus; Johannes B van Goudoever; Frans J Walther
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

6.  Mortality and Major Morbidity of Very-Low-Birth-Weight Infants in Germany 2008-2012: A Report Based on Administrative Data.

Authors:  Elke Jeschke; Alexandra Biermann; Christian Günster; Thomas Böhler; Günther Heller; Helmut D Hummler; Christoph Bührer
Journal:  Front Pediatr       Date:  2016-03-22       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.